Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Cash (2017 - 2025)

Historic Change in Cash for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to -$1.1 million.

  • Puma Biotechnology's Change in Cash fell 109736.84% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 863.87%. This contributed to the annual value of -$15.4 million for FY2024, which is 29490.11% down from last year.
  • As of Q3 2025, Puma Biotechnology's Change in Cash stood at -$1.1 million, which was down 109736.84% from -$8.4 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Cash ranged from a high of $25.2 million in Q3 2022 and a low of -$25.9 million during Q3 2021
  • For the 5-year period, Puma Biotechnology's Change in Cash averaged around -$2.2 million, with its median value being -$1.8 million (2022).
  • As far as peak fluctuations go, Puma Biotechnology's Change in Cash tumbled by 307803.68% in 2021, and later skyrocketed by 22990.34% in 2023.
  • Quarter analysis of 5 years shows Puma Biotechnology's Change in Cash stood at -$816000.0 in 2021, then plummeted by 115.56% to -$1.8 million in 2022, then surged by 229.9% to $2.3 million in 2023, then decreased by 14.4% to $2.0 million in 2024, then crashed by 158.13% to -$1.1 million in 2025.
  • Its Change in Cash was -$1.1 million in Q3 2025, compared to -$8.4 million in Q2 2025 and -$6.2 million in Q1 2025.